Metastatic Colorectal Cancer

Survival for patients with metastatic colorectal cancer has improved steadily since 2012, according to retrospective study results.

In this video interview, Cecilia Monge, MD, MPH, FACP, from the NCI Center for Cancer Research at NIH, discussed the SUNLIGHT trial data presented at ASCO Gastrointestinal Cancers Symposium.

A phase 3 trial of trilaciclib in combination FOLFOXIRI and bevacizumab for patients with metastatic colorectal cancer met its co-primary endpoints but will be terminated based on early efficacy data, according to the agent’s manufacturer.

Benjamin Schlechter, MD, of Dana-Farber Cancer Institute, discussed the mature phase 3 data on the addition of bevacizumab to trifluridine/tipiracil in refractory colorectal cancer in a video interview with Healio.

In a video interview with Healio, Benjamin Schlechter, MD, of Dana-Farber Cancer Institute, spoke about “the first combination to show efficacy in colorectal cancer in a specialized population.”

The FDA granted accelerated approval to tucatinib in combination with trastuzumab for adults with RAS wild-type, HER2-positive metastatic or unresectable colorectal cancer, according to a company press release.

Trifluridine-tipiracil plus bevacizumab was not superior to capecitabine plus bevacizumab but presented no new safety concerns in patients with unresectable metastatic colorectal cancer who are ineligible for intensive treatment.

The addition of bevacizumab to trifluridine and tipiracil extended OS among patients with advanced colorectal cancer, according to a topline data announcement.

The FDA lifted its clinical hold on a trial designed to evaluate CYAD-101, an investigational chimeric antigen receptor T-cell therapy.

In this video, Smitha S. Krishnamurthi, MD, discussed the results of the TRIPLETE trial, which she said showed no improvement when irinotecan was added to FOLFOX panitumumab in patients with mostly unresectable RAS and BRAF wild-type left-sided metastatic colorectal cancer.